# A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight

> **NCT00542009** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 252 (actual)

## Conditions studied

- Weight Management
- Treatment Of Obesity

## Interventions

- **DRUG:** CE-326,597 100 mg QD
- **DRUG:** CE-326,597 50 mg QD
- **DRUG:** CE-326,597 25 mg QD
- **DRUG:** Placebo
- **DRUG:** CE-326,597 5mg QD

## Key facts

- **NCT ID:** NCT00542009
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2012-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00542009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00542009, "A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00542009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*